Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics
MIRON-TROP
1 other identifier
observational
227
2 countries
2
Brief Summary
Pilot trial to determine diagnostic efficacy of post-reperfusion troponin kinetics in detection of hemorrhagic myocardial infarction
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 8, 2022
CompletedFirst Submitted
Initial submission to the registry
May 14, 2023
CompletedFirst Posted
Study publicly available on registry
May 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 21, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 21, 2025
CompletedSeptember 8, 2025
September 1, 2025
2.5 years
May 14, 2023
September 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic Threshold
Levels of markers in hemorrhagic infarct vs. non-hemorrhagic infarct
48 hours
Secondary Outcomes (6)
Peak levels of serum troponin-I
48 hours
Area under the curve (AUC) for serum troponin-I
48 hours
Hemorrhagic infarct size
48 hours
Hemorrhagic infarct volume
48 hours
Hemorrhagic infarct microvascular obstruction
48 hours
- +1 more secondary outcomes
Eligibility Criteria
The study population consists of individuals aged 18 to 80 who have been diagnosed with acute ST-elevation myocardial infarction (STEMI) and are scheduled for emergency percutaneous coronary intervention (PCI).
You may qualify if:
- Age ≥ 18 years
- Index STEMI
- Coronary angiogram with PCI to occur irrespective of the onset of the symptoms.
- Ability to provide informed consent for themselves
You may not qualify if:
- History of prior myocardial infarction,
- Cardiogenic shock,
- Patients who present with current cardiac arrest
- Any contraindication to cardiac CMR (claustrophobia, pacemaker or cardiac defibrillator, known allergy to gadolinium),
- Presence of permanent atrial fibrillation,
- Unconscious patient,
- Severe renal insufficiency (creatinine clearance ≤ 30 ml/min/m2 or renal replacement therapy),
- Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
IU Methodist Hospital
Indianapolis, Indiana, 46202, United States
Synergy Cardiovascular Research Center, Synergy Superspecialty Hospital
Rajkot, Gujarat, India
Related Publications (1)
Vora KP, Kalra A, Shah CD, Bhatt K, Kumar A, Pandya T, Poptani V, Chan SF, Singh D, Jambunathan N, Subramanian R, Youssef K, Kanakasabai S, Finney R, Desai A, Kreutz RP, Kovacs RJ, Raman SV, Bhatt DL, Dharmakumar R. In-Hospital Mortality in Hemorrhagic Myocardial Infarction. NEJM Evid. 2025 Sep;4(9):EVIDoa2400294. doi: 10.1056/EVIDoa2400294. Epub 2025 Aug 26.
PMID: 40858097DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Keyur P Vora, MD FACC
Faculty
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Vice Chair of Research, Medical Imaging Research Institute
Study Record Dates
First Submitted
May 14, 2023
First Posted
May 24, 2023
Study Start
July 8, 2022
Primary Completion
January 21, 2025
Study Completion
January 21, 2025
Last Updated
September 8, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share